Insider Trading March 6, 2026

Delek US EVP Executes $1.54M Stock Sale; Q4 2025 Earnings Show Big EPS Beat, Revenue Shortfall

Israel Joseph disposes of 38,000 shares as the stock trades near its 52-week high amid mixed quarterly results

By Leila Farooq DK
Delek US EVP Executes $1.54M Stock Sale; Q4 2025 Earnings Show Big EPS Beat, Revenue Shortfall
DK

Delek US Holdings Executive Vice President Israel Joseph sold 38,000 shares on March 4, 2026, generating $1.54 million at a weighted average price of $40.65. The company recently reported a strong adjusted EPS beat for Q4 2025 but missed revenue expectations. Shares trade near a 52-week high, while third-party analysis flags potential overvaluation and the company remains unprofitable on a trailing-twelve-month basis.

Key Points

  • Israel Joseph sold 38,000 Delek US shares on March 4, 2026, raising $1.54 million at a weighted average price of $40.65; post-sale direct ownership is 55,623 shares.
  • Delek US reported a Q4 2025 adjusted EPS of $2.31 versus expectations of -$0.07 (a 3,400% positive surprise), while revenue of $2.43 billion missed the $2.55 billion forecast by 4.71%; investors pushed the stock higher after the release.
  • The stock trades at $42.29, close to its 52-week high of $45.74 after a 209% gain over the past year; InvestingPro flags the shares as appearing overvalued and notes the company remains unprofitable on a trailing-twelve-month EPS of -$0.34.

Insider sale details

Executive Vice President Israel Joseph sold 38,000 shares of Delek US Holdings common stock on March 4, 2026, receiving a total of $1.54 million for the disposal. The transaction carried a weighted average sale price of $40.65 per share, with individual trade prices reported between $40.10 and $40.93. After the sale, Joseph directly holds 55,623 shares of the company's common stock.

Market context and valuation

Delek US shares are trading at $42.29, a level close to the company's 52-week high of $45.74, following a pronounced 209% increase over the past year. Independent analysis from InvestingPro included in market commentary indicates that the stock appears overvalued at current levels. The company carries a market capitalization of $2.53 billion, while remaining unprofitable on a trailing-twelve-month basis with negative earnings per share of $0.34.

Quarterly results: contrast between profit and top line

In its fourth-quarter 2025 financials, Delek US reported an adjusted earnings per share of $2.31, which outpaced analysts' expectations of -$0.07 — a positive surprise quantified at 3,400%. Revenue for the same period totaled $2.43 billion, falling short of the anticipated $2.55 billion and representing a 4.71% negative surprise. The company’s results therefore present a pronounced divergence: a sizable earnings beat alongside a revenue miss.

Market reaction

Investors responded favorably to the earnings release, and the company's stock rose following the report. These moves in the share price have occurred while the stock remains near its yearly high and amid the noted valuation concerns by third-party analysis.


Note on available analysis

Additional proprietary tips and deeper insights for investors in Delek US are available through InvestingPro, which advertises further guidance and specific valuation tools for interested subscribers.

Risks

  • Valuation risk: Third-party analysis cited in market commentary characterizes the stock as appearing overvalued at current prices - this affects equity investors and market participants tracking valuation-sensitive strategies.
  • Profitability uncertainty: Despite the quarterly earnings beat, the company reported a negative trailing-twelve-month EPS of $0.34, signaling ongoing unprofitability that may concern fundamental investors.
  • Revenue shortfall risk: The fourth-quarter revenue missed analyst estimates by 4.71%, highlighting top-line pressure that could influence future investor sentiment and affect sector valuations.

More from Insider Trading

Energy Services of America President Buys $83,327 in Shares as Company Advances Capital Plan Mar 23, 2026 iBio CEO Martin Brenner Buys $24,918 of Company Stock as Firm Reports Preclinical Data and Raises Capital Mar 23, 2026 iBio CFO Buys $50,000 of Stock Amid Pipeline and Financing Updates Mar 23, 2026 Keysight CEO Disposes $483,430 in Stock as Company Broadens AI and Cybersecurity Test Offerings Mar 23, 2026 Foxx Development EVP Disposes of 759 Shares in Two Trades; Company Reports Board Addition Mar 20, 2026